Progesterone carboxymethyloxime
Chemical compound
From Wikipedia, the free encyclopedia
Progesterone carboxymethyloxime, or progesterone 3-(O-carboxymethyl)oxime (P4-3-CMO), is a progestin which was never marketed.[1][2][3] It is an oral prodrug of progesterone with improved pharmacokinetic properties.[1] The compound was developed in an attempt to address the poor oral pharmacokinetics of progesterone, including its very low bioavailability and short biological half-life.[1][2] These properties of progesterone are thought to be caused by its low water solubility and high metabolic clearance rate due to rapid degradation in the intestines and liver.[1][2] Drugs with low aqueous solubility are not absorbed well in the intestines because their dissolution in water is limited.[4]
- 50909-89-2
118860-31-4 (potassium)
| Clinical data | |
|---|---|
| Other names | P4-3-CMO; Progesterone 3-carboxymethyloxime; Progesterone 3-(O-carboxymethyl)oxime; 3-(O-Carboxymethyl-oximino)progesterone; [[(20-Oxopregn-4-en-3-ylidene)amino]oxy]acetic acid |
| Routes of administration | By mouth[1] |
| Drug class | Progestogen; Neurosteroid |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.875 |
| Chemical and physical data | |
| Formula | C23H33NO4 |
| Molar mass | 387.520 g·molâ1 |
| 3D model (JSmol) | |
| |
| |
P4-3-CMO (as the potassium salt) showed water solubility that was increased by more than four orders of magnitude relative to progesterone (solubility = 9.44 mol/L and 0.0006 mol/L, respectively).[2] In addition, it showed an in vitro terminal half-life in rat liver microsomes that was 363-fold longer than that of progesterone (half-life = 795.5 minutes and 2.2 minutes, respectively).[1] As such, P4-3-CMO could have both improved absorption and increased metabolic stability relative to progesterone.[1][2] However, the compound has not been further assessed nor studied in humans.[1][2]